Anne Gruaz

Title: Anne Gruaz: Innovator in Neurotensin Analogues

Introduction

Anne Gruaz is a prominent inventor based in Paris, France. She has made significant contributions to the field of medical research, particularly in the development of neurotensin analogues. Her work focuses on targeting neurotensin receptor-positive tumors, which are critical in the fight against various types of cancer.

Latest Patents

Anne Gruaz holds a patent for "Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors." This invention relates to a new neurotensin analogue, or a salt thereof, that is useful for targeting neurotensin receptor-positive tumors. These tumors include ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma, and astrocytoma. She has 1 patent to her name.

Career Highlights

Throughout her career, Anne has worked with esteemed organizations such as the National Institute of Health and Medical Research and Iason GmbH. Her research has been pivotal in advancing the understanding and treatment of neurotensin receptor-positive tumors.

Collaborations

Anne has collaborated with notable professionals in her field, including Didier Pelaprat and Jacques Barbet. These collaborations have enriched her research and contributed to her innovative work.

Conclusion

Anne Gruaz is a trailblazer in the development of neurotensin analogues, making significant strides in cancer research. Her contributions are vital for the advancement of targeted therapies in oncology.